Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.67 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.56 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.56 |
| ▸ | AGXT | P21549 | 1/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
| ▸ | IDH1 | O75874 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL661546 | 0.89 | CYP2A6 (0.71) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL48281 | 0.84 | CYP2A6 (0.56) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL5336214 | 0.81 | CYP2A6 (0.56) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL10673407 | 0.81 | CYP2A6 (0.67) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL5337360 | 0.81 | CYP2A6 (0.56) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL16399948 | 0.81 | CYP2A6 (0.56) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL346786 | 0.81 | CYP2A6 (0.56) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL4283571 | 0.81 | CYP2A6 (0.56) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL7345698 | 0.81 | CYP2A6 (0.56) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL2098350 | 0.81 | CYP2A6 (0.56) | CYP2A6ASIC3LOXL2AGXTADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-20210040066-A1 | TETRAHYDROISOQUINOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2021-02-11 | — | — | US | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| EP-3022199-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2016-05-25 | — | — | EP | disclosed |
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| WO-2015008872-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-01-22 | — | — | WO | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| EP-1814848-B9 | 2,3,4-SUBSTITUTED-CYCLOPENTANONES AS THERAPEUTIC AGENTS | ALLERGAN INC (US) | 2011-12-21 | — | — | EP | disclosed |
| EP-1814848-B1 | 2,3,4-SUBSTITUTED-CYCLOPENTANONES AS THERAPEUTIC AGENTS | ALLERGAN INC (US) | 2010-07-28 | — | — | EP | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| EP-2168944-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-03-31 | — | — | EP | disclosed |
| WO-2009153536-A1 | 1-AZA-BICYCLO [2.2.2] OCTANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009153536-A1 | 1-AZA-BICYCLO [2.2.2] OCTANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
| US-7183324-B2 | 2,3,4-substituted cyclopentanones as therapeutic agents | ALLERGAN, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183324-B2 | 2,3,4-substituted cyclopentanones as therapeutic agents | ALLERGAN, INC. (US) | 2007-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | CYP2A6 3084/4885ASIC3 1037/4885LOXL2 3866/4885 |
| US-20210040066-A1 | TETRAHYDROISOQUINOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | PDE4B, PDE7B, PDE4A | CYP2A6 568/4885ASIC3 3887/4885LOXL2 3547/4885 |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | HLA-B, HLA-A, HLA-C | CYP2A6 211/4885ASIC3 2870/4885LOXL2 4038/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | CYP2A6 3084/4885ASIC3 1037/4885LOXL2 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.